Jacobs Levy Equity Management, Inc Nektar Therapeutics Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 2,793,204 shares of NKTR stock, worth $3.27 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,793,204
Previous 2,873,192
2.78%
Holding current value
$3.27 Million
Previous $3.56 Million
1.94%
% of portfolio
0.01%
Previous 0.02%
Shares
18 transactions
Others Institutions Holding NKTR
# of Institutions
147Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$18.6 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$17.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$15.4 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$11 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$10.8 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $219M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...